Table 1 Site-distinguished γ results of patient-specific QA
Beam model | Delivered gantry | Malignancy | Criteria | Mean passing rate (%) | Range |
|---|---|---|---|---|---|
Shared GTR2 model | GTR2 (M2G2) | Prostate | 2 mm/3% | 96.83 | 90.6–99.4 |
3 mm/3% | 98.98 | 96.7–100.0 | |||
Lung | 2 mm/3% | 97.67 | 94.3–100.0 | ||
3 mm/3% | 99.06 | 97.4–100.0 | |||
NPC | 2 mm/3% | 98.36 | 92.3–100.0 | ||
3 mm/3% | 99.69 | 97.9–100.0 | |||
GTR4 (M2G4) | Prostate | 2 mm/3% | 97.25 | 92.8–99.9 | |
3 mm/3% | 99.00 | 96.7–100.0 | |||
Lung | 2 mm/3% | 97.91 | 93.7–100.0 | ||
3 mm/3% | 99.19 | 97.4–100.0 | |||
NPC | 2 mm/3% | 98.24 | 92.1–100.0 | ||
3 mm/3% | 99.58 | 98.3–100.0 | |||
Shared GTR4 model | GTR2 (M4G2) | Prostate | 2 mm/3% | 96.74 | 90.8–99.9 |
3 mm/3% | 98.91 | 96.7–100.0 | |||
Lung | 2 mm/3% | 97.26 | 92.6–100.0 | ||
3 mm/3% | 98.91 | 96.6–100.0 | |||
NPC | 2 mm/3% | 98.44 | 93.0–100.0 | ||
3 mm/3% | 99.46 | 96.3–100.0 | |||
GTR4 (M4G4) | Prostate | 2 mm/3% | 97.34 | 93.9–99.7 | |
3 mm/3% | 99.10 | 96.7–100.0 | |||
Lung | 2 mm/3% | 97.81 | 94.1–100.0 | ||
3 mm/3% | 98.99 | 96.7–100.0 | |||
Head | 2 mm/3% | 98.49 | 93.1–100.0 | ||
3 mm/3% | 99.41 | 96.4–100.0 |